The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.

[1]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[2]  E. Ofili,et al.  Diastolic heart failure: The forgotten manifestation of hypertensive heart disease , 2004, Current hypertension reports.

[3]  W. Gaasch,et al.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. , 2004, The New England journal of medicine.

[4]  A. Coats,et al.  The epidemiological enigma of heart failure with preserved systolic function , 2004, European journal of heart failure.

[5]  K. Swedberg,et al.  Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. , 2004, Journal of the American College of Cardiology.

[6]  G. Fonarow,et al.  The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. , 2003, Reviews in cardiovascular medicine.

[7]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[8]  M. Pfeffer,et al.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.

[9]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[10]  N. Freemantle,et al.  The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .

[11]  J. Cohn,et al.  Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) , 2002, Circulation.

[12]  K. Swedberg,et al.  Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology , 2002, European journal of heart failure.

[13]  J. Carroll,et al.  Heart Failure With a Normal Ejection Fraction: Is Measurement of Diastolic Function Necessary to Make the Diagnosis of Diastolic Heart Failure? , 2001, Circulation.

[14]  C. Held,et al.  Regression of left ventricular hypertrophy in human hypertension with irbesartan , 2001, Journal of hypertension.

[15]  J. Gardin,et al.  Importance of heart failure with preserved systolic function in patients ≥65 years of age , 2001 .

[16]  J. Gardin,et al.  Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. , 2001, The American journal of cardiology.

[17]  R. Califf,et al.  Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. , 2000, The American journal of cardiology.

[18]  M. Hori,et al.  Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. , 2000, Cardiovascular research.

[19]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[20]  D. Levy,et al.  Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. , 1999, Journal of the American College of Cardiology.

[21]  D. Kitzman,et al.  Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. , 1999, Journal of the American College of Cardiology.

[22]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[23]  J. Cohn,et al.  Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT) , 1996, Journal of the American College of Cardiology.

[24]  R. Carney,et al.  A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. , 1995, The New England journal of medicine.

[25]  H. Schunkert,et al.  Distribution and Functional Significance of Cardiac Angiotensin Converting Enzyme in Hypertrophied Rat Hearts , 1993, Circulation.

[26]  H. Schunkert,et al.  Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. , 1990, The Journal of clinical investigation.

[27]  C. Hom.  Arizona , 1982, The Electric Interurban Railways in America.

[28]  B. Clark.  Kentucky , 1897, The Journal of comparative medicine and veterinary archives.

[29]  Sandra L. Berger.  Connecticut , 1896, The Journal of comparative medicine and veterinary archives.

[30]  John T. Cunningham,et al.  New Jersey , 1896, The Journal of Comparative Medicine and Veterinary Archives.

[31]  E. Lazartigues.  Louisiana State University Health Sciences Center , 1999 .